Appointment of International Advisory Board for BIT225
Filed with ASX · · 2 pages · English
Earlier from Biotron
- Presentation at BIO 2019
- Presentation of BIT225-009 HIV-1 Phase 2 data
- Response to ASX aware letter
- Biotron Secures $4.7 Million Underwriting Agreement
- $1.07 million R&D Tax Incentive Received
Later from Biotron
- Presentation to Investors
- Biotron Secures $5.1 Million Underwriting Agreement
- Biotron to Test its Compounds Against Coronavirus
- BIT225 restores immune function in HIV-1 infections
- R&D Tax Refund Received
Follow Biotron into a list and get an email when it puts out news.
Follow Biotron